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Novel approaches are needed to eliminate pituitary 
adenomas, since the invasiveness of bone; dura or 
cavernous sinus may adversely affect the outcome 
of tumors and compromise the disease-free survival 
of patients. Jaita et al., detected that Fas and FasL are 
expressed in several anterior pituitary cell types from 
female rats, mainly in lactotropes and somatotropes. 
In addition, they reported that Fas activation induces 
apoptosis of lactotropes and somatotropes,[1] suggesting 
that FasL is involved in the maintenance of tissue 
homeostasis in the anterior pituitary gland and could 
have potential benefit for the treatment of pituitary 
adenomas.
Abstract
Purpose: To detect the expressions of Fas/DcR3 and to investigate the cytotoxic effects 
of RGD-FasL on pituitary adenoma cells. Materials and Methods: Fas/DcR3 mRNAs 
were detected by Reverse transcription polymerase chain reaction (RT-PCR) and their 
surface expressions were measured by flow cytometry. Cytotoxicities exerted by FasL and 
newly-constructed RGD-FasL on tumor cells were measured with 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The apoptotic cells were examined 
by electron microscopy and the induced apoptosis was determined by agarose gel 
electrophoresis. The cell cycle was assessed by flow cytometry with ANNEXIN V FITC/
PI. The expressions of caspases, Bcl-2, RANKL and JNK2 were detected by Western 
blotting. Results: Fas/DcR3 was expressed in GH3/MMQ/AtT20 cells. The cytotoxic 
effects of RGD-FasL on tumor cells were seen in a dose-dependent manner. These cells 
showed the same sensitivity to RGD-FasL as to FasL. RGD-FasL induced apoptosis and 
G1/G0 arrest. The expressions of caspase-8/9/3, RANKL, JNK2 were increased while 
that of Bcl-2 was decreased with treatment of RGD-FasL. Conclusions: Fas can be a novel 
target for the treatment of pituitary adenomas. RGD-FasL induces apoptosis of pituitary 
adenoma cells through caspase activation.
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Pituitary adenoma cell lines GH3, MMQ, AtT20 were 
cultured and underwent RT-PCR analysis for expressions 
of Fas and DcR3 mRNA, followed by flow cytometry 
analysis for expressions of Fas and DcR3 protein. The 
FasL gene was constructed by overlapping PCR, then was 
cloned into pGEX-5X-1, which contained a GST tag. RGD 
was fused onto the N-terminal of FasL. The two proteins, 
FasL and RGD-FasL, were purified through a GST resin 
column (Novagen, USA). The effects of FasL/RGD-FasL 
on cell proliferation were measured using an MTT-based 
assay, in the presence of various concentrations (1.5625, 
3.125, 6.25, 12.5, 25, 50 µg/mL) of FasL/RGD-FasL for 
12 h. The apoptotic cells were examined by electron 
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microscopy. For DNA fragmentation analysis, tumor cells 
were treated with RGD-FasL (3.125, 6.25, 12.5, 25, 50 µg/
mL) for 4 h. Then, cell cycle distribution and apoptosis 
were determined by flow cytometry with ANNEXIN 
V FITC/PI. Western blot analysis was performed for 
protein expressions of caspase-8/9/3, RANKL, JNK2 and 
Bcl-2 (Sigma, USA). The mechanism of apoptosis was 
confirmed with caspase inhibition assay.
Results
There was no significant difference in the mRNA 
expression level of Fas between the three cell lines 
examined. The mRNA expression of DcR3 in At 
T20 cells was lower than that in GH3/MMQ cells. 
Approximately 13.7% of GH3 cells, 25.5% of MMQ cells, 
22.2% of AtT20 cells expressed Fas protein, while about 
23.9% of GH3 cells, 24.1% of MMQ cells, 4.6% of AtT20 
cells expressed DcR3 protein. The cytotoxic effects of 
RGD-FasL on tumor cells were seen in a dose-dependent 
manner. These cells showed the same sensitivity to 
RGD-FasL as to FasL. Electron microscopy showed 
that GH3 cells treated with RGD-FasL (50 µg/ml) for 4 h 
caused the shrinkage and condensation of nucleus and 
cytoplasm, the margination of chromatin along with 
nuclear membrane, and the formation of apoptotic 
bodies [Figure 1]. After treatment of GH3 cells with 
RGD-FasL at various concentrations for 4 h, a typical 
ladder pattern of inter-nucleosomal DNA fragmentation 
was detected using an agarose gel electrophoresis 
[Figure 2]. The cell death mode induced by RGD-FasL 
was assessed by Flow cytometry with ANNEXIN V 
FITC kit. The apoptotic cells increased significantly in 
both GH3 cell line and AtT20 cell line [Figure 3]. And 
the expressions of caspase-8/9/3, RANKL, JNK2 were 
increased while that of Bcl-2 was decreased [Figure 4]. 
The caspase inhibitor, Z-VAD-FMK, could inhibit the 
apoptosis induced by RGD-FasL.
Discussion
The αVβ3 integrin is one of the most specific markers 
for targeted delivery of cytotoxic agents to the tumor 
vasculature.[2] In our study, the high affinity αVβ3 
selective ligand, Arg-Gly-Asp (RGD) peptide was used 
for newly-developed RGD-FasL (produced by our team), 
which allows active targeting and delivery of FasL to 
sites of tumor angiogenesis devoid of systemic toxicity. 
There have been a series of inspiring tests showing that 
RGD-FasL exerts cytotoxic activity on U138 and Hela 
cell lines more than FasL (data not shown).
It was demonstrated that the somatolactotrophic 
tumor cell line GH3 and the corticotrophic tumor cell 
line AtT20 express Fas.[3,4] In GH3 and AtT20 cells, 
overexpression of Fas strongly enhanced cell death by 
apoptosis. Considering that apoptosis plays a central 
role in regulation of pituitary tissue homeostasis, the 
imbalance between cell death and proliferation in 
favor of cell survival could result in pituitary adenoma 
formation. Whether the existence and difference of 
expressions of Fas/DcR3 on tumor cells could be the 
cause of selective apoptosis induced by FasL remains 
unclear and needs to be determined further.
Our results demonstrate that functionally, RGD-FasL 
has the same effective cytotoxicity as the FasL does on 
pituitary adenoma cells; RGD-FasL induces apoptosis 
through caspase activation. We conclude that RGD-FasL 
could probably be considered as a novel therapeutical 
candidate for the treatment of pituitary adenomas. 
Further studies are currently underway on animal 
models to determine the targeted cytotoxicity of RGD-
FasL towards tumor-associated vasculature and tumor 
Figure 1: Electron microscopy (a) untreated GH3 cell; 
(b-d) GH3 cells treated with RGD-FasL (50 µg/ml) for 4 h
Figure 2: GH3 cells were treated with various concentrations (Lane 
1-5 represent 3.125, 6.25, 12.5, 25, 50 µg/ml) of RGD-FasL. After 
4 h, fragmented DNA was collected and separated by agarose gel 
electrophoresis and visualized by ethidium bromide staining
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cells. Part of our further studies suggests that pituitary 
tumor stem cells might be self-existent and RGD-FasL 
may probably target pituitary tumor stem cells and 
suppress the tumor growth through αVβ3.
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Abbreviations
FasL: Fas ligand 
DcR: decoy receptor 
RGD: tripeptide sequence Arg-Gly-Asp
RGD-FasL: fusion protein of RGD and Fas ligand
GH: Growth hormone
RT-PCR: reverse transcription polymerase chain reaction
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide
JNK: c-Jun N-terminal kinase
RANKL: Receptor activator of nuclear factor kappa B 
ligand 
Bcl-2: B-cell lymphoma leukemia 2
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FasL with ANNEXIN V FITC/PI. (a) untreated GH3 cells; (b) treated GH3 
cells; (c) untreated AtT20 cells; (d) treated AtT20 cells
Accepted on 01-02-2009
Source of Support: Nil, Conß ict of Interest: None declared.
